EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antineoplastic therapy affects the in vitro phenotype and functionality of healthy human bone marrow-derived mesenchymal stromal cells

Bo Scherer iD, Lucienne Bogun, Annemarie Koch, Paul Jäger, Uwe Maus, Laura Schmitt, Karina S Krings, Sebastian Wesselborg, Rainer Haas, Thomas Schroeder, Stefanie Geyh

Archives of Toxicology · 2025

DOI: 10.1007/s00204-024-03898-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Toxicology, 2025. Verfasst von Bo Scherer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldor…. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Antineoplastic Agents. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While antineoplastic therapies aim to specifically target cancer cells, they may also exert adverse effects on healthy tissues, like healthy hematopoietic stem and progenitor cells (HSPC), leading to hematotoxicity as a common side effect. Mesenchymal stromal cells (MSC) are a major component of the bone marrow (BM) microenvironment, regulating normal hematopoiesis, while their susceptibility to anticancer therapies and contribution to therapy-related hematotoxicity remains largely unexplored. To address this, we investigated the effects of etoposide, temozolomide, 5-azacitidine, and venetoclax on healthy BM-derived MSC functionality. Doses below therapeutic effects of etoposide (0.1–0.25 µM) inhibited cellular growth and induced cellular senescence in healthy MSC, accompanied by an increased mRNA expression of CDKN1A , decreased trilineage differentiation capacity, and insufficient hematopoietic support. Pharmacological doses of 5-azacitidine (2.5 µM) shifted MSC differentiation capacity by inhibiting osteogenic capacity but enhancing the chondrogenic lineage, as demonstrated by histochemical staining and on mRNA level. At the highest clinically relevant dose, neither venetoclax (40 nM) nor temozolomide (100 µM) exerted any effects on MSC but clearly inhibited cellular growth of cancer cell lines and primary healthy HSPC, pointing to damage to hematopoietic cells as a major driver of hematotoxicity of these two compounds. Our findings show that besides HSPC, also MSC are sensitive to certain antineoplastic agents, resulting in molecular and functional alterations that may contribute to therapy-related myelosuppression. Understanding these interactions could be helpful for the development of strategies to preserve BM MSC functionality during different kinds of anticancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsAntineoplastic AgentsHumansCell DifferentiationTemozolomidePhenotypeCell ProliferationSulfonamidesCell Line, TumorEtoposideCellular SenescenceCells, CulturedOsteogenesisBone Marrow CellsHematopoietic Stem CellsBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

Antineoplastic therapyBone marrow microenvironmentDifferentiationHematotoxicityMSC

Substanzen

Antineoplastic AgentsTemozolomideSulfonamidesEtoposidevenetoclaxBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Department of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany.
  • Department of Orthopedic Surgery and Traumatology, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University, Moorenstraße 5, 40225, Duesseldorf, Germany.
  • Institute for Molecular Medicine 1, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University, Universitätsstraße 1, 40225, Duesseldorf, Germany.
  • Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany. thomas.schroeder@uk-essen.de.
  • Department of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany. stefanie.geyh@med.uni-d…

ORCID-Profile: Bo Scherer

Förderung

  • Deutsche Forschungsgemeinschaft
  • Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts

Zitieren

APA

Scherer, B., Bogun, L., Koch, A., Jäger, P., Maus, U., Schmitt, L., Krings, K. S., Wesselborg, S., Haas, R., Schroeder, T., & Geyh, S. (2025). Antineoplastic therapy affects the in vitro phenotype and functionality of healthy human bone marrow-derived mesenchymal stromal cells. Archives of Toxicology. https://doi.org/10.1007/s00204-024-03898-w

Vancouver

Scherer B, Bogun L, Koch A, Jäger P, Maus U, Schmitt L, et al. Antineoplastic therapy affects the in vitro phenotype and functionality of healthy human bone marrow-derived mesenchymal stromal cells. Archives of Toxicology. 2025. doi:10.1007/s00204-024-03898-w

BibTeX
@article{Scherer2025,
  author = {Scherer, Bo and Bogun, Lucienne and Koch, Annemarie and Jäger, Paul and Maus, Uwe and Schmitt, Laura and Krings, Karina S and Wesselborg, Sebastian and Haas, Rainer and Schroeder, Thomas and Geyh, Stefanie},
  title = {Antineoplastic therapy affects the in vitro phenotype and functionality of healthy human bone marrow-derived mesenchymal stromal cells},
  journal = {Archives of Toxicology},
  year = {2025},
  doi = {10.1007/s00204-024-03898-w}
}
Kostenlos starten →